Fig. 2From: A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)Fasting HVPG response to serelaxin. Lines represent individual participant changes in HVPG following 2-h infusion of serelaxin (n = 9). Filled diamonds indicate the group mean at each time point. HVPG hepatic venous pressure gradient, ns not significantBack to article page